These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 32687669)

  • 21. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
    Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
    J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
    Chung W; Kim KA; Jang ES; Ki M; Choi HY; Jeong SH
    J Gastroenterol Hepatol; 2019 Apr; 34(4):776-783. PubMed ID: 30462841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era.
    Poovorawan K; Pan-Ngum W; White LJ; Soonthornworasiri N; Wilairatana P; Wasitthankasem R; Tangkijvanich P; Poovorawan Y
    PLoS One; 2016; 11(9):e0163095. PubMed ID: 27631382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan.
    Fukuda H; Yano Y; Sato D; Ohde S; Noto S; Watanabe R; Takahashi O
    Pharmacoeconomics; 2020 Mar; 38(3):297-306. PubMed ID: 31761994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
    Nan YM; Liu LD; Zhao W; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):919-922. PubMed ID: 31941253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Potential application of sofosbuvir-based treatment for chronic hepatitis C in China].
    Zhang QF; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):233-237. PubMed ID: 29804397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
    Ridruejo E; Cheinquer H; Marciano S; Mendizabal M; Piñero F; Wolff FH; de Araujo A; Coelho Borges S; Kliemann D; Fleck A; de Maman Í; Nader LA; Garrastazul P; Bermúdez C; Haddad L; Gadano A; Silva M
    J Viral Hepat; 2019 Oct; 26(10):1200-1209. PubMed ID: 31141239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
    Fathi H; Clark A; Hill NR; Dusheiko G
    BMC Infect Dis; 2017 Nov; 17(1):722. PubMed ID: 29145802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
    Li JP; Chen XF; Yan Q; Zhang YJ; Xie ZW; Xia Y; Guan YJ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):831-837. PubMed ID: 33105927
    [No Abstract]   [Full Text] [Related]  

  • 34. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
    Abozeid M; Alsebaey A; Abdelsameea E; Othman W; Elhelbawy M; Rgab A; Elfayomy M; Abdel-Ghafar TS; Abdelkareem M; Sabry A; Fekry M; Shebl N; Rewisha E; Waked I
    Int J Infect Dis; 2018 Oct; 75():109-114. PubMed ID: 30077791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project.
    Coyer L; Njoya O; Njouom R; Mossus T; Kowo MP; Essomba F; Boers A; Coutinho R; Ondoa P;
    Trop Med Int Health; 2020 Sep; 25(9):1098-1109. PubMed ID: 32502290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
    Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
    Taneja S; Duseja A; De A; Mehta M; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Dhiman RK; Chawla Y
    Dig Dis Sci; 2018 May; 63(5):1334-1340. PubMed ID: 29484572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.
    Pfeil AM; Reich O; Guerra IM; Cure S; Negro F; Müllhaupt B; Lavanchy D; Schwenkglenks M
    PLoS One; 2015; 10(5):e0126984. PubMed ID: 25974722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals.
    Pariente A; Arpurt JP; Remy AJ; Rosa-Hezode I; Causse X; Heluwaert F; Macaigne G; Henrion J; Renou C; Schnee M; Salloum H; Hommel S; Pilette C; Arotcarena R; Barjonet G; Lison H; Bourhis F; Jouannaud V; Pauwels A; Le-Bricquir Y; Geagea E; Condat B; Ripault MP; Zanditenas D; de Montigny-Lenhardt S; Labadie H; Tissot B; Maringe E; Cadranel JF; Hagege H; Lesgourgues B;
    Ann Hepatol; 2019; 18(1):193-202. PubMed ID: 31113590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
    J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.